This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
New Strong Sell Stocks for July 18th
by Zacks Equity Research
ACHC, CNL and RDY have been added to the Zacks Rank #5 (Strong Sell) List on July 18, 2025.
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Roku (ROKU) Surges 10.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Roku (ROKU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
EchoStar (SATS) Moves 49.1% Higher: Will This Strength Last?
by Zacks Equity Research
EchoStar (SATS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
by Zacks Equity Research
Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?
by Zacks Equity Research
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals
by Zacks Equity Research
Dr. Reddy's, Sandoz and Teva Pharmaceuticals have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes
by Sundeep Ganoria
Despite the impact of dynamic shifts in the regulatory landscape for the Zacks Medical - Generic Drugs industry, new product launches should provide some respite to RDY, SDZNY and TEVA.
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar
by Zacks Equity Research
Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
by Zacks Equity Research
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
by Ekta Bagri
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio.
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
by Ekta Bagri
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?
by Zacks Equity Research
Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Zacks Analyst Blog Highlights Qifu, Yatra Online and Dr. Reddy's
by Zacks Equity Research
Qifu, Yatra Online and Dr. Reddy's are included in this Analyst Blog.
3 Emerging Market Stocks to Buy as 2024 Wraps Up
by Urmimala Biswas
Here, we have picked three emerging market stocks, QFIN, YTRA and RDY, which are expected to show robust growth in 2025 on their growth strategies and fundamentals.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio
by Zacks Equity Research
RDY enjoys a strong foothold in the global generics market due to its deep generic drugs pipeline. Its efforts to strengthen its biosimilars portfolio are commendable.
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma
by Zacks Equity Research
Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow
by Zacks Equity Research
RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets.